Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019
31 mai 2019 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Announces Upcoming Presentation of Phase 3b data of NEPA (fosnetupitant / palonosetron) IV at ASCO 2019 The NEPA IV formulation was evaluated for safety in the AC setting. Lugano,...
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association
07 mai 2019 11h19 HE
|
Helsinn Healthcare S.A.
Helsinn nominated as a Swiss Biotech Success Story 2019/2020 by the Swiss Biotech Association Switzerland, May 7, 2019: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced
19 mars 2019 18h00 HE
|
Helsinn Healthcare S.A.
Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced Mihir Shah of UE LifeSciences Inc. has been selected as the winner of the 2019 Lyfebulb-Helsinn...
Helsinn initiates two new global Phase III studies with anamorelin
07 mars 2019 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn initiates two new global Phase III studies with anamorelin Helsinn committed to anamorelin which is being evaluated for weight loss and anorexia in patients with advanced non small cell lung...
Helsinn Investment Fund: Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology
27 févr. 2019 08h15 HE
|
Helsinn Healthcare S.A.
Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer...
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
19 févr. 2019 02h30 HE
|
Helsinn Healthcare S.A.
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics Luxembourg, February 19, 2019: Helsinn Investment Fund S.A, SICAR, a fund focused on early-stage investment opportunities in areas of...
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
14 févr. 2019 15h22 HE
|
Helsinn Healthcare S.A.
Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in the Frontline Treatment of Older AML Patients Unfit for Intensive Chemotherapy, in Blood...
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care
31 janv. 2019 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Provides Educational Grant for ESMO’s Preceptorship for Supportive and Palliative Care Lugano, Switzerland, January 31, 2019 – Helsinn, a Swiss pharmaceutical group focused on...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
02 janv. 2019 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
21 déc. 2018 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat Licensing rights are worldwide excluding US, Canada, Japan and South America Lugano, Switzerland and Florence, Italy,...